Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine
The company lifted its sales outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
Read original reporting ↗← Story archive
Business
Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine
The company lifted its sales outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
Follow the evidence
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →